DEA Temporarily Classifies Synthetic 7-OH as Schedule I Opioid

The Drug Enforcement Administration (DEA) announced on July 1, 2026, plans to temporarily classify 7-hydroxymitragynine (7-OH) and three related substances—MP, MGM-15, and MGM-16—as Schedule I controlled substances. This designation places the compounds in the same category as heroin and LSD, subjecting their manufacture and sale to severe federal penalties. The ban targets products exceeding 0.050% 7-OH by dry weight or containing over 1 milligram of the compound.

This regulatory action follows a determination by the Department of Health and Human Services that these synthetic substances have no accepted medical use and a high potential for abuse. The move is scheduled to take effect 30 days after formal publication on July 6 and will remain in place for two years, with a possible third-year extension. DEA Administrator Terrance Cole stated the action specifically targets highly concentrated synthetic products rather than botanical kratom, which remains legal.

The decision marks a shift from a May 11 statement by President Donald Trump, who indicated his administration was considering approving natural 7-OH. Despite this, Health and Human Services Secretary Robert F. Kennedy Jr. supported the ban, characterizing the substances as dangerous opioids. The American Kratom Association also backed the move to protect the reputation of natural kratom leaf. Conversely, the Holistic Alternative Recovery Trust opposed the classification, arguing it lacks a scientific basis. Simultaneously, Kansas reclassified 7-OH and kratom as Schedule 1, and Virginia implemented new laws prohibiting specific sales and requiring warning labels.